About: Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
Creator	Li, Juan Liu, Dong Luo, Pan Liu,
Source	Elsevier; Medline; PMC; WHO
abstract	Abstract Coronavirus disease 2019 (COVID-19) caused by a previously unknown pathogen named severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has now become a pandemic threat to the whole world. However, there are no vaccines or specific treatment against the new virus. Therefore, there is an urgent need for advancing novel therapeutic interventions for COVID-19. Glycyrrhizin, a triterpene saponine, is valuable for its various biological functions and pharmacology effects. In this brief article, we will discuss the therapeutic potential of glycyrrhizin for COVID-19 from the perspective of its pharmacological action including binding angiotensin converting enzyme II (ACE2), down-regulating proinflammatory cytokines, inhibiting the accumulation of intracellular ROS, inhibiting thrombin, inhibiting the hyperproduction of airway exudates, and inducing endogenous interferon.
has issue date	2020-04-24(xsd:dateTime)
bibo:doi	10.1016/j.ijantimicag.2020.105995
bibo:pmid	32335281
has license	els-covid
sha1sum (hex)	7f27c5c6a9be958c4230bab2e73fd746356df551
schema:url	https://doi.org/10.1016/j.ijantimicag.2020.105995
resource representing a document's title	Pharmacologic perspective: glycyrrhizin may be an efficacious therapeutic agent for COVID-19
has PubMed Central identifier	PMC7180159
has PubMed identifier	32335281
schema:publication	Int J Antimicrob Agents
resource representing a document's body	covid:7f27c5c6a9be958c4230bab2e73fd746356df551#body_text
is schema:about of	named entity 'vaccines' named entity 'intracellular' named entity 'inhibiting' named entity 'Highlights' named entity 'COVID-19' named entity 'REGULATING' named entity 'INCLUDING' named entity 'DISCUSS' named entity 'potential' named entity 'pathogen' named entity 'article' named entity 'caused' named entity 'proinflammatory cytokines' named entity 'effects' named entity 'perspective' named entity 'COVID-19' named entity 'ROS' named entity 'virus' named entity 'saponine' named entity 'Coronavirus disease 2019' named entity 'pharmacological action' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'cytokine storm' named entity 'proinflammatory cytokines' named entity 'JNK' named entity 'glycyrrhizin' named entity 'infection' named entity 'SARS-CoV' named entity 'pharmacology' named entity 'COVID-19' named entity 'infection' named entity 'pharmacology' named entity 'p38' named entity 'COVID' named entity 'COVID' named entity 'Glycyrrhizin' named entity 'nuclear factor' named entity 'receptor' named entity 'SARS-CoV-2' named entity 'interferon' named entity 'endogenous' named entity 'ACE2' named entity 'glucocorticoid' named entity 'SARS-CoV' named entity 'clinical symptoms' named entity 'COVID' named entity 'heart disease' named entity 'glycyrrhizin' named entity 'SARS-CoV' named entity 'SARS-CoV-2' named entity 'interferons' named entity 'viral adsorption' named entity 'inflammatory response' named entity 'glycyrrhizin' named entity 'adverse reaction' named entity 'cytokine storm' named entity 'pathogen' named entity 'World Health Organization' named entity 'multiple organ failure' named entity 'saponine' named entity 'ROS' named entity 'viral adsorption' named entity 'cytokine' named entity 'antioxidants' named entity 'glycyrrhizin' named entity 'Glycyrrhizin' named entity 'glycyrrhizin' named entity 'virus entry' named entity 'cytokines' named entity 'COVID-19' named entity 'coronavirus' named entity 'down-regulating' named entity 'administrated' named entity 'glucocorticoids' named entity 'cytokine storm' named entity 'receptor' named entity 'thrombin'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software